Connective Tissue Research最新文献_第3页

Drug repurposing for osteoarthritis disease modification in the early 21^st century. 21世纪初治疗骨关节炎疾病的药物再利用

IF 2.1 4区医学

Connective Tissue Research Pub Date : 2025-09-01 Epub Date: 2025-08-02 DOI: 10.1080/03008207.2025.2538562

Ivar van Galen, Marjolein M J Caron, Guus G H van den Akker, Tim J M Welting

{"title":"Drug repurposing for osteoarthritis disease modification in the early 21st century.","authors":"Ivar van Galen, Marjolein M J Caron, Guus G H van den Akker, Tim J M Welting","doi":"10.1080/03008207.2025.2538562","DOIUrl":"10.1080/03008207.2025.2538562","url":null,"abstract":"Osteoarthritis (OA) is a leading cause of disability worldwide, significantly impacting patient mobility and quality of life. Its increasing prevalence presents a growing socioeconomic burden. Despite extensive research, no FDA-approved disease-modifying osteoarthritis drugs (DMOADs) exist, leaving patients reliant on symptomatic treatments like NSAIDs, corticosteroids, and joint replacement surgeries. A major challenge in OA drug development is the heterogeneity of the disease. Traditional approaches that target single molecular pathways often fail to address the multifactorial nature of OA. Given the high failure rate and costs of novel drug development, drug repurposing has emerged as a promising alternative. Several repurposed drugs, predominantly those affecting inflammation (e.g. Methotrexate, Adalimumab), metabolism (e.g. Metformin, Liraglutide) and bone homeostasis (e.g. Risedronate, Clodronate) have been investigated for OA. However, inconsistent clinical trial results underscore the need for improved screening, patient stratification, and mechanistic understanding. Recent insights into OA pathophysiology, such as the role of cellular senescence, mitochondrial dysfunction, and translational alterations, highlight novel targets for repurposing efforts. The future of OA drug repurposing will likely be shaped by advancements in high-throughput screening, artificial intelligence-driven drug discovery, and strategies that align treatments with patient-specific disease mechanisms. By integrating these innovations, drug repurposing holds potential to deliver DMOADs and improve patient outcomes worldwide.","PeriodicalId":10661,"journal":{"name":"Connective Tissue Research","volume":" ","pages":"481-489"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in molecular imaging for osteoarthritis. 骨关节炎分子影像学研究进展。

IF 2.1 4区医学

Connective Tissue Research Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI: 10.1080/03008207.2025.2535425

Maria I Menendez Montes, Christine T N Pham, Yongjian Liu, Farshid Guilak

{"title":"Advances in molecular imaging for osteoarthritis.","authors":"Maria I Menendez Montes, Christine T N Pham, Yongjian Liu, Farshid Guilak","doi":"10.1080/03008207.2025.2535425","DOIUrl":"10.1080/03008207.2025.2535425","url":null,"abstract":"Osteoarthritis (OA) is a complex, multifactorial joint disease and a leading contributor to global disability. Despite its high prevalence and socioeconomic burden, no curative or preventive therapies currently exist. The ability to detect early OA, or even \"pre-OA\" could provide the opportunity for earlier interventions. Current conventional imaging modalities such as radiography and Magnetic resonance imaging (MRI) are limited by their inability to detect early pathophysiological molecular changes. This review highlights the potential of positron emission tomography (PET) imaging to transform the diagnosis and therapeutic monitoring of OA. PET has emerged as a transformative tool capable of visualizing early metabolic, inflammatory, and cellular alterations. But while current clinical PET imaging with [18F]Fluorodeoxyglucose ([18F]-FDG) and [18F] Sodium fluoride ([18F]-NaF) can assess synovial inflammation and subchondral bone remodeling, their lack of specificity hinders further advances. We also review the recent development of radiotracers targeting specific immune and mesenchymal cell populations, such as translocator protein (TSPO) and fibroblast activation protein inhibitor (FAPI) that have demonstrated potential for characterizing the inflammatory endotype in OA and monitoring treatment response. Given the lack of validated cell-specific tracers, limited studies in early-stage or asymptomatic OA, and few longitudinal data sets, future research should prioritize development and validation of pathophysiology-specific tracers and incorporation of PET into longitudinal and interventional studies. This evolving field holds promise not only for advancing OA preclinical research but also for informing precision diagnostics and early therapeutic strategies in clinical practice.","PeriodicalId":10661,"journal":{"name":"Connective Tissue Research","volume":" ","pages":"407-413"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the bioactivity of synovial fluid in osteoarthritis: implications for disease understanding and management. 探讨骨关节炎滑膜液的生物活性：对疾病理解和管理的意义。

IF 2.1 4区医学

Connective Tissue Research Pub Date : 2025-09-01 Epub Date: 2025-07-04 DOI: 10.1080/03008207.2025.2525953

Keanu Hh Haenen, Guus Gh van den Akker, Marjolein Mj Caron, Tonia L Vincent, Tim Jm Welting

引用次数: 0

Gene therapy pipelines for osteoarthritis: current innovations, operational challenges, and future directions. 骨关节炎的基因治疗管道：当前的创新、操作挑战和未来方向。

IF 2.1 4区医学

Connective Tissue Research Pub Date : 2025-09-01 Epub Date: 2025-07-04 DOI: 10.1080/03008207.2025.2520319

Valtteri Peitso, Karman Ng, Ron Ellis, Jean-Yves Reginster, Christopher H Evans, Ali Mobasheri

{"title":"Gene therapy pipelines for osteoarthritis: current innovations, operational challenges, and future directions.","authors":"Valtteri Peitso, Karman Ng, Ron Ellis, Jean-Yves Reginster, Christopher H Evans, Ali Mobasheri","doi":"10.1080/03008207.2025.2520319","DOIUrl":"10.1080/03008207.2025.2520319","url":null,"abstract":"Osteoarthritis (OA) is a multifactorial joint disease characterized by progressive cartilage degradation, synovial inflammation, and subchondral bone remodeling. Despite its significant global health burden, there are currently no disease-modifying pharmacological therapies for OA. Gene therapy, leveraging viral and non-viral vectors to deliver therapeutic transgenes into the joint environment, shows significant promise. This mini-review highlights recent innovations in OA gene therapy pipelines, focusing on Platforms employing recombinant adenovirus, adeno-associated virus (AAV), and herpes simplex virus vectors. Strategies include AAV-mediated delivery of interleukin-1 receptor antagonist (IL-1Ra) and truncated nkx3.2 transcription factor to modulate inflammation and promote chondrocyte survival. Non-viral approaches, such as plasmid DNA encoding interleukin-10, are also under investigation. Emerging data from preclinical and clinical studies demonstrate the feasibility of achieving sustained, intra-articular transgene expression with therapeutic efficacy in animal models and early-phase human trials. However, challenges persist, including immune barriers to repeat dosing, variability in vector performance, and the high costs of treatment. Additionally, agerelated declines in transduction efficiency, the heterogeneity of OA, and systemic metabolic influences complicate therapeutic outcomes. To overcome current regulatory obstacles, future research must prioritize the refinement of vector systems to enhance safety, potency, and specificity, as well as the development of combination therapies integrating genetic and conventional approaches, targeting pain and improving function. Gene therapy has transformative potential for improving OA management and an important priority is multidisciplinary collaboration to translate preclinical innovations into accessible, effective treatments for a highly heterogeneous and aging patient population.","PeriodicalId":10661,"journal":{"name":"Connective Tissue Research","volume":" ","pages":"458-465"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cross-regulation of inflammation and metabolic mechanisms in osteoarthritis: recent advances bridging the gap to novel treatments. 骨关节炎炎症和代谢机制的交叉调节：最近的进展弥合了新治疗方法的差距。

IF 2.1 4区医学

Connective Tissue Research Pub Date : 2025-09-01 Epub Date: 2025-05-07 DOI: 10.1080/03008207.2025.2500530

Yousef Abu-Amer

{"title":"Cross-regulation of inflammation and metabolic mechanisms in osteoarthritis: recent advances bridging the gap to novel treatments.","authors":"Yousef Abu-Amer","doi":"10.1080/03008207.2025.2500530","DOIUrl":"10.1080/03008207.2025.2500530","url":null,"abstract":"Osteoarthritis (OA) is a debilitating degenerative disease of the joints and one of the most prevalent joint disorders affecting millions of individuals worldwide. This disease is highlighted by significant morbidity owing to encumbering joint pain and functional impairment. OA ensues following disruption of normal homeostasis in the joint resulting from aging, metabolic changes, or as a consequence of joint injury (referred to as post-traumatic OA). These processes are largely driven by low-grade inflammation that gradually compromises the anabolic and protective activities of joint resident cells including chondrocytes, synovial fibroblasts (SFs) and immune cells. Ample research suggests that the process of cartilage deterioration is the endpoint of complex pathologic processes culminating with synovitis, subchondral bone sclerosis, osteophyte formation, aberrant remodeling, and ultimately articular cartilage degradation. There remains a great need for identifying early markers and a \"window of opportunity\" to enable timely interventions in OA. However, this effort is hampered by the complex nature of the disease and its comorbidities. Joint holistic approaches using recent unbiased multi-omic tools are currently at the forefront promising better understanding of OA development. Currently, there are no meaningful disease-modifying drugs to treat OA, with surgical procedures as the ultimate effective intervention for end stage OA patients. The disability, pain, and surgical costs associated with OA management position this disease among the costliest and onerous for our society. This mini review will highlight advances in the last two decades and major obstacles limiting progress in OA research with particular emphasis on metabolic and inflammatory comorbidities.","PeriodicalId":10661,"journal":{"name":"Connective Tissue Research","volume":" ","pages":"339-344"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biological impact of meniscus injury on post-traumatic osteoarthritis. 半月板损伤对创伤后骨关节炎的生物学影响。

IF 2.1 4区医学

Connective Tissue Research Pub Date : 2025-09-01 Epub Date: 2025-04-14 DOI: 10.1080/03008207.2025.2487916

Nathan H Varady, Scott A Rodeo

{"title":"Biological impact of meniscus injury on post-traumatic osteoarthritis.","authors":"Nathan H Varady, Scott A Rodeo","doi":"10.1080/03008207.2025.2487916","DOIUrl":"10.1080/03008207.2025.2487916","url":null,"abstract":"Post-traumatic osteoarthritis (PTOA) is a common and debilitating problem following meniscal injury, which may lead to pain, loss of function, and early joint failure. Over the past 25 years, clinical, laboratory, and translational studies have greatly improved our understanding of PTOA pathogenesis and prevention. Clinical studies have established the benefit of meniscal preservation in preventing PTOA, leading to a significant increase in meniscus repair. Similarly, improved understanding of the biomechanical importance of the meniscal root attachment has increased focus on the detection and treatment of meniscal root injuries. Laboratory studies have demonstrated a preliminary mechanistic pathway of PTOA development following meniscal injury, whereby injury and altered joint loading stimulate a pro-inflammatory response that leads to both articular cartilage breakdown and impaired meniscal healing. In vitro evidence suggests that mechanical loading of the meniscus may ameliorate this catabolic response, with implications for treatment and rehabilitation protocols. Numerous animal models have emerged, allowing for in vivo assessment of PTOA initiation and offering a platform to test potential therapeutic targets. Despite these advances, meniscal repair remains imperfect and is not always possible, and investigations translating laboratory findings to the human setting have been limited. Future directions include further characterizing the immune and cellular responses to meniscal injury, investigating therapies to target the pro-inflammatory cascade and enhance meniscal healing, and developing new models to better distinguish PTOA pathogenesis in human subjects. Continued laboratory, translational, and clinical research efforts are required to identify treatment strategies to reduce the burden of PTOA after meniscal injury.","PeriodicalId":10661,"journal":{"name":"Connective Tissue Research","volume":" ","pages":"387-392"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Key insights and implications of cartilage degradation in osteoarthritis. 骨关节炎中软骨退化的关键见解和意义。

IF 2.1 4区医学

Connective Tissue Research Pub Date : 2025-09-01 Epub Date: 2025-07-21 DOI: 10.1080/03008207.2025.2536153

Lucienne A Vonk

{"title":"Key insights and implications of cartilage degradation in osteoarthritis.","authors":"Lucienne A Vonk","doi":"10.1080/03008207.2025.2536153","DOIUrl":"10.1080/03008207.2025.2536153","url":null,"abstract":"Progressive degradation of articular cartilage is characteristic of osteoarthritis (OA), but OA is more than a wear-and-tear disease of the cartilage. It is a complex, multifactorial disease affecting all joint tissues, amplified by local and systemic inflammation. Chondrocytes play a crucial role in cartilage homeostasis and various molecular pathways that leading to their catabolic state have been identified. Cartilage degradation fragments and direct exposure of chondrocytes to extracellular matrix molecules provide feedback loops that further stimulate the catabolic profile. Synovial inflammation and subchondral bone changes enhance cartilage degradation by changing the joint environment, secreting pro-inflammatory cytokines and proteolytic enzymes, and attracting immune cells. The heterogeneity of the disease is underscored by the recognition on various phenotypes and endotypes, although consensus on classification of subtypes is lacking. In the last 25 years, we have learned that timely treatment of joint injuries and repairing the meniscus are the best options to delay cartilage degradation and the development of post-traumatic OA. In addition, clinical studies have shown that cartilage thickness can be restored, but it does not necessarily provide clinical improvements. So far, there is no disease modifying OA drug (DMOAD) available. The development of DMOADs is partially hindered by the requirement of long preclinical and clinical studies, as cartilage degradation is a slow process. Availability of biomarkers as surrogate endpoint could accelerate the development. Biomarker panels for early diagnosis and patient stratification could also advance the field. Currently emerging treatment approaches, such as using regenerative medicine, promising for successful treatment.","PeriodicalId":10661,"journal":{"name":"Connective Tissue Research","volume":" ","pages":"393-398"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The osteoarthritis pain enigma and how biomechanics research can lead to new solutions. 骨关节炎疼痛之谜和生物力学研究如何带来新的解决方案。

IF 2.1 4区医学

Connective Tissue Research Pub Date : 2025-09-01 Epub Date: 2025-07-03 DOI: 10.1080/03008207.2025.2512938

Kyle D Allen, Yenisel Cruz-Almeida, Alejandro J Almarza

{"title":"The osteoarthritis pain enigma and how biomechanics research can lead to new solutions.","authors":"Kyle D Allen, Yenisel Cruz-Almeida, Alejandro J Almarza","doi":"10.1080/03008207.2025.2512938","DOIUrl":"10.1080/03008207.2025.2512938","url":null,"abstract":"The primary function of our joints is to provide pain-free movement. However, with osteoarthritis (OA), the joint's structures are damaged, potentially leading to chronic joint pain. While it is logical to assume chronic OA pain relates to tissue destruction, a direct relationship between joint structure and pain is not the full story. For the last 25 years, epidemiologic data estimates that there are as many asymptomatic cases of OA as symptomatic cases in the United States. Thus, the relationship between OA pathology and painful symptoms is more complex than \"more damage leads to more pain.\" This OA pain enigma is one of the outstanding challenges in the field. Since the ultimate function of the joint is to provide pain-free movement, this narrative review discusses our opinions on how biomechanics can continue to advance our understanding of joint function within the context of chronic OA pain. Using multiscale mechanics, we have learned critical lessons on how loads are transferred during movement. Tissue structure-function modeling has begun to reveal how articular cartilage produces its extraordinary mechanical functions. Moreover, biomechanics principles are being incorporated into rehabilitation and \"prehabilitation\" strategies in the clinic. Within these biomechanical lessons, a critical challenge remains for the OA joint-is our goal pain free movement or restoration of the joint? Within the OA pain enigma, the relationship between pain and function remains closely entwined, and our outlook sees a critical role for biomechanics research advancing our understanding of chronic OA pain.","PeriodicalId":10661,"journal":{"name":"Connective Tissue Research","volume":" ","pages":"367-372"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical and molecular landscape of post-traumatic osteoarthritis. 创伤后骨关节炎的临床和分子特征。

IF 2.1 4区医学

Connective Tissue Research Pub Date : 2025-09-01 Epub Date: 2025-04-23 DOI: 10.1080/03008207.2025.2490797

Kyohei Takase, Patrick C McCulloch, Jasper H N Yik, Dominik R Haudenschild

{"title":"Clinical and molecular landscape of post-traumatic osteoarthritis.","authors":"Kyohei Takase, Patrick C McCulloch, Jasper H N Yik, Dominik R Haudenschild","doi":"10.1080/03008207.2025.2490797","DOIUrl":"10.1080/03008207.2025.2490797","url":null,"abstract":"Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage breakdown, chronic pain, and disability. Post-traumatic osteoarthritis (PTOA), a secondary form of OA, arises from joint injuries and consistently accounts for a proportion of symptomatic cases. Unlike primary OA, PTOA has a well-defined initiation point, presenting an opportunity for early intervention. Over the past two decades, research has shifted from a cartilage-centric view to a broader understanding of OA as a multifaceted disease involving inflammation, oxidative stress, and complex molecular crosstalk between chondrocytes, synoviocytes, osteocytes, and immune cells. Key inflammatory mediators, such as IL-1β, IL-6, TNF-α, and Wnt/β-catenin signaling, drive disease progression. Advances in imaging, biomarker discovery, and animal models have provided insights into early disease mechanisms. However, gaps remain in understanding the molecular events that trigger PTOA onset, the interplay between joint tissues, and the identification of reliable early biomarkers. Delayed diagnosis, lack of disease-modifying therapies, and OA's complexity remain critical barriers. Future directions should focus on precision medicine integrating biomarkers, imaging, and artificial intelligence for early diagnosis and risk stratification. Emerging regenerative and gene therapies, while promising, would benefit from moving beyond single-pathway targeting, as OA's multifaceted nature makes a combination approach desirable to simultaneously address inflammation, oxidative stress, cartilage matrix degradation, and tissue repair. Multidisciplinary collaborations between clinicians, molecular biologists, and bioengineers are essential to translating discoveries into effective interventions. A paradigm shift toward early, personalized treatment strategies is necessary to improve long-term outcomes in PTOA and OA management.","PeriodicalId":10661,"journal":{"name":"Connective Tissue Research","volume":" ","pages":"373-379"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pain mechanisms in osteoarthritis: recent discoveries and opportunities ahead. 骨关节炎的疼痛机制：最近的发现和未来的机会。

IF 2.1 4区医学

Connective Tissue Research Pub Date : 2025-09-01 Epub Date: 2025-08-08 DOI: 10.1080/03008207.2025.2531414

Daniel B Hoffman, Rachel E Miller, Anne-Marie Malfait

{"title":"Pain mechanisms in osteoarthritis: recent discoveries and opportunities ahead.","authors":"Daniel B Hoffman, Rachel E Miller, Anne-Marie Malfait","doi":"10.1080/03008207.2025.2531414","DOIUrl":"10.1080/03008207.2025.2531414","url":null,"abstract":"Clinically meaningful therapeutics targeting osteoarthritis pain have remained elusive over the years, but the collective understanding of mechanisms driving joint pain has continued to progress, offering a hopeful future. Recent significant discoveries in the field include detailed characterizations of structural and functional neuroplasticity within the joint, highlighting the contributions of non-neuronal cells in mediating this neuroplasticity. Notably, nerve growth factor has been identified as an important mediator of nociceptor sensitization and is expressed by many cells in the OA joint (e.g, chondrocytes, synovial fibroblasts, macrophages, osteoclasts). The release of pain-sensitizing mediators from non-neuronal cells is largely attributed to tissue damage and inflammation; however, the role of metabolism in OA pain development has begun to garner more attention and is discussed further in this narrative minireview. Altered whole-body and cellular metabolism can influence pain through various mechanisms, including adipokine hormonal signaling and metabolite production from catabolic pathways. The emerging potential of glucagon-like peptide-1 receptor agonists to treat osteoarthritis pain and possible mechanisms are discussed. Finally, the future of elucidating pain mechanisms and translational success will require novel experimental approaches and increased use of human tissue-based models, which are briefly discussed.","PeriodicalId":10661,"journal":{"name":"Connective Tissue Research","volume":" ","pages":"359-366"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12392683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0